Bortezomib (CED0001407)

Bortezomib (C19H25BN4O4) is a compound with an average molecular weight of 384.24 g/mol. Bortezomib belongs to the amino acids, peptides, and analogues, a subclass of carboxylic acids and derivatives within the organic compounds. Biologically, it functions as a proteasome inhibitor (PMC10351539, PMC11698957, PMC9323819, PMC9687107). Its recorded protein targets include Proteasome subunit beta type-1 (PSMB1), Proteasome subunit beta type-5 (PSMB5), and Serine protease 1 (PRSS1). The compound is found in healthcare, pharmaceuticals & veterinary products as an antineoplastic agent, as well as in household cleaning & consumer products (pipe accessories, non electric simulated smoking devices) and electrical & electronic equipment (electric hearing aids, radio transmission systems, antennas). Recorded exposure routes include intravenous, parenteral, subcutaneous, intratendinous, and intracavernous. Bortezomib is used as a treatment for cancer (PMC10351539), melanoma (PMC7226512), lymphoma (PMC7532106, PMC9323819), multiple myeloma (PMC3983165, PMC5030385, PMC5053712, PMC6223128, PMC7115922, PMC9387011), renal failure (PMC7109734), and acute renal failure (PMC3227886). It has therapeutic effects on atherosclerosis (PMC12947462) and multiple myeloma (PMC4352933, PMC5916964, PMC6223128, PMC9387011). Associated health effects include nausea, vomiting, fatigue, rash, and itching (PMC10351539), as well as neutropenia and diarrhea (PMC7873303). Other reported effects include thrombosis, hypertension (PMC12946163), congestive heart failure (PMC12946163, PMC5679835), and neuropathic pain (PMC4559079). It is linked to neuropathy (PMC6223128, PMC9387011) and an increase in neuropathy (PMC4382664, PMC7214419, PMC7873303). Additionally, it is associated with thrombocytopenia (PMC10039009, PMC10351539, PMC11795829, PMC7873303) and an increase in thrombocytopenia (PMC4753325).